Prevention

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

The clearance for the phase 2 preventive trial will seek the oral antiviral's benefit in elderly care facilities.

David Ho, MD, shares insight into the public and scientific health shortcomings which burdened the nation back in March.

A look at the history of vaccines, our society's current standing in public health and vaccine preparedness, and what may come in the near future.

What role does new research play in combating public vaccination concerns?

A discussion on the process by which the FDA regulates vaccine candidates at a time when COVID-19 candidates are progressing.

What happens if we don't get a COVID-19 vaccine? Patrick Soon-Shiong, MD, describes another potential route for research efforts, which could also supplement vaccine development.

A benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection

Dr. Pol Vandenbroucke describes the individual and collective risks associated with rising antibiotic resistance.

Dr. Pol Vandenbroucke talks about what makes antibiotic stewardship so important to clinicians and researchers.

Dr. Pol Vandenbroucke explains how the development of health and civil society infrastructure around the world helps to slow antimicrobial resistance.

Dr. Pol Vandenbroucke describes the alarming global threat of antimicrobial resistance.

Providing oral antibiotics to people who inject drugs with infections may reduce hospital readmissions.

Expansion of antimicrobial stewardship strategies to include vertical methods represents an opportunity for programs, both new and established, to further optimize antimicrobial use.

Patrick Soon-Shiong, MD, describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.

The COVID-19 pandemic has put the brakes on HIV cure research, but investigators report recent progress and promising pathways nonetheless.

Armand Balboni, MD, PHD, CEO of Appili Therapeutics, discusses work with favipiravir on a new front for the drug — the global search for COVID-19 treatment and prevention therapies.

Barriers to recommended vaccine coverage for low-income American adults include disparity in Medicaid programs and low reimbursement amounts, a new study found.

The attenuated virus in oral polio vaccines has developed the ability to evolve and spread to humans. Now, investigators have developed a new vaccine without the ability to make such changes.

Disparate reimbursement policies disincentivize clinicians from vaccinating adults with lower incomes.

MenQuadfi is the only FDA approved quadrivalent meningococcal vaccine that is indicated for individuals 2 through 56 years of age and older.

Health care settings such as hospitals, clinics, assisted living facilities, and physician offices depend on the circulation of clean air that is free of mold, bacteria, viruses, and fungi.

The authors of the review recommend the continued use of MMR vaccines on a mass scale.

A new survey found that parents in Spain were the most supportive of vaccinations when compared with their counterparts in 4 other European countries.

Whole genome sequencing revealed little overlap between MDROs found in pets and pet owners.